Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Feb 1;154(2):167-174.
doi: 10.1001/jamadermatol.2017.3631.

Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial

Martin A Weinstock  1   2 , Soe Soe Thwin  3 , Julia A Siegel  1 , Kimberly Marcolivio  1   2 , Alexander D Means  1   2 , Nicholas F Leader  1   2 , Fiona M Shaw  1 , Daniel Hogan  4 , David Eilers  5 , Susan M Swetter  6 , Suephy C Chen  7 , Sharon E Jacob  8 , Erin M Warshaw  9 , George P Stricklin  10 , Robert P Dellavalle  11 , Navjeet Sidhu-Malik  12 , Nellie Konnikov  13 , Victoria P Werth  14 , Jonette E Keri  15 , Leslie Robinson-Bostom  2 , Robert J Ringer  16 , Robert A Lew  3 , Ryan Ferguson  13 , John J DiGiovanna  17 , Grant D Huang  18 ; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group
Affiliations
Randomized Controlled Trial

Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial

Martin A Weinstock et al. JAMA Dermatol. .

Abstract

Importance: Keratinocyte carcinoma (ie, cutaneous basal and squamous cell carcinoma) is the most common cancer in the United States.

Objective: To determine whether topical fluorouracil could prevent surgically treated keratinocyte carcinoma.

Design, setting, and participants: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial was a randomized, double-blind, placebo-controlled trial of topical fluorouracil for chemoprevention of keratinocyte carcinoma. Participants were recruited from May 2009 to September 2011 from 12 Veterans Affairs medical centers and followed until June 30, 2013. Participants were veterans (n = 932) with a history of at least 2 keratinocyte carcinomas in the past 5 years; almost all were white males and the median age was 70 years.

Interventions: Application of fluorouracil, 5%, (n = 468) or vehicle control cream (n = 464) to the face and ears twice daily for 2 to 4 weeks upon randomization.

Main outcomes and measures: Surgically treated keratinocyte, basal cell, and squamous cell carcinoma risk on the face and ears in the first year after enrollment; and time to first surgically treated keratinocyte, basal cell, and squamous cell carcinoma. The a priori hypothesis was that fluorouracil would be effective in preventing these cancers.

Results: Of 932 participants (916 men [98%]; 926 white [99%]; median age, 70 years), 299 developed a basal cell carcinoma end point (95 in year 1) and 108 developed a squamous cell carcinoma end point (25 in year 1) over 4 years (median follow-up, 2.8 years). Over the entire study, there was no difference between treatment groups in time to first keratinocyte, basal cell, or squamous cell carcinoma. During the first year, however, 5 participants (1%) in the fluorouracil group developed a squamous cell carcinoma vs 20 (4%) in the control group, a 75% (95% CI, 35%-91%) risk reduction (P = .002). The 11% reduction in basal cell carcinoma risk during year 1 (45 [10%] in the fluorouracil group vs 50 [11%] in the control group) was not statistically significant (95% CI, 39% reduction to 31% increase), nor was there a significant effect on keratinocyte carcinoma risk. However, a reduction in keratinocyte carcinomas treated with Mohs surgery was observed.

Conclusions and relevance: A conventional course of fluorouracil to the face and ears substantially reduces surgery for squamous cell carcinoma for 1 year without significantly affecting the corresponding risk for basal cell carcinoma.

Trial registration: clinicaltrials.gov Identifier: NCT00847912.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Weinstock is employed by Brown Dermatology, Inc (Brown University Department of Dermatology’s faculty practice) in addition to his listed affiliations. Dr Weinstock served as a consultant to AbbVie, Castle, and Celgene. Dr Dellavalle receives editorial stipends from the Journal of Investigative Dermatology and the Journal of the American Academy of Dermatology and has received grant support from Pfizer Pharmaceuticals for an independent research grant to the University of Colorado (for development of patient decision).

Figures

Figure 1.
Figure 1.. Randomization, Stratification, and Follow-up of Study Participants
Participants were recruited from May 2009 to September 2011 and included veterans with a history of at least 2 keratinocyte carcinomas in the past 5 years. Of 954 patients enrolled and randomized, 932 were included in the primary analysis: 468 in the fluorouracil group and 464 in the control group. HIPAA indicates Health Insurance Portability and Accountability Act.
Figure 2.
Figure 2.. Proportion of Participants With SCC by Treatment Group
Participants who completed a 2- to 4-week course of topical fluorouracil, 5%, applied twice daily to the face and ears reduced the risk of SCC requiring surgery at those sites by 75% for 1 year. No effect was seen over 4 years. SCC indicates squamous cell carcinoma.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Karimkhani C, Boyers LN, Dellavalle RP, Weinstock MA. It’s time for “keratinocyte carcinoma” to replace the term “nonmelanoma skin cancer.” J Am Acad Dermatol. 2015;72(1):186-187. - PubMed
    1. American Cancer Society Cancer facts & figures 2012. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts.... Accessed May 24, 2016.
    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. - PubMed
    1. Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med. 2015;48(2):183-187. - PMC - PubMed
    1. Yoon J, Phibbs CS, Chow A, Pomerantz H, Weinstock MA. Costs of keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis treatment in the Veterans Health Administration. Dermatol Surg. 2016;42(9):1041-1047. - PubMed

Publication types

MeSH terms

Associated data